Innoviva (INVA) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Innoviva (INVA) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Innoviva |
1.65 Bn |
1.05 Bn |
75.83 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
1,449.66% |
| Dec 31, 2025 |
-115.37% |
| Sep 30, 2025 |
41.18% |
| Jun 30, 2025 |
236.70% |
| Mar 31, 2025 |
-342.06% |
| Dec 31, 2024 |
-968.84% |
| Sep 30, 2024 |
103.50% |
| Jun 30, 2024 |
-194.96% |
| Mar 31, 2024 |
655.24% |
| Dec 31, 2023 |
-108.02% |
| Sep 30, 2023 |
6,309.84% |
| Jun 30, 2023 |
-96.33% |
| Mar 31, 2023 |
437.58% |
| Dec 31, 2022 |
-103.89% |
| Sep 30, 2022 |
28,177.21% |
| Jun 30, 2022 |
-94.05% |
| Mar 31, 2022 |
360.80% |
| Dec 31, 2021 |
-108.35% |
| Sep 30, 2021 |
-18.56% |
| Jun 30, 2021 |
-5.50% |
